{"id":400,"date":"2024-11-07T14:54:10","date_gmt":"2024-11-07T14:54:10","guid":{"rendered":"https:\/\/stemvacs.therapeuticsolutionsint.com\/?page_id=400"},"modified":"2024-11-07T14:55:01","modified_gmt":"2024-11-07T14:55:01","slug":"carcinoma-stemvacs-ipsc-chimera-a-gal","status":"publish","type":"page","link":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/carcinoma-stemvacs-ipsc-chimera-a-gal\/","title":{"rendered":"Carcinoma – StemVacs-iPSC Chimera\/A-Gal"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.21.0″ _module_preset=”default” background_color=”gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311″ custom_padding=”61px|||||” collapsed=”on” global_colors_info=”{%22gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311%22:%91%22background_color%22%93}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-47px|||||” custom_padding=”2px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

The following list of cancer immunotherapies<\/strong> are available for licensing under U.S. Patent Publication No.: 20220403330<\/span><\/a>.<\/span><\/p>\n

Compositions Capable of Stimulating Immunity Towards Tumor Blood Vessels<\/strong><\/p>\n

\n
\n
\n
Abstract<\/div>\n
\n
Disclosed are novel means, protocols, and compositions of matter for eliciting an immune response against blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the \u03b1-Gal epitope (Gal\u03b11,3Gal\u03b11,4G1cNAc-R).<\/span><\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-99px|auto||auto||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-149px|||||” custom_padding=”37px|||||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]<\/p>\n


\n
\n